Mantle Cell Lymphoma

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.

A blood test may help to identify a subset of patients with mantle cell lymphoma and determine the management of outcomes of these individuals.

New drug regimens are not only personalizing the treatment of patients with mantle cell lymphoma, but they’re also improving outcomes, too, explained Chaitra S. Ujjani, M.D.

A certain group of patients may not be candidates for common therapies, explained Bijal D. Shah, M.D.

This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.

One of the things I think about is the future. All cancer patients know we have two futures: One where things go well, and one where they don't.

Deferring treatment may actually be beneficial for some patients with mantle cell lymphoma (MCL), according to recent research.

While the treatment landscape of mantle cell lymphoma (MCL) has continued to evolve in recent years, researchers and clinicians alike are still at a loss for curative strategies. But immunotherapy may help.

Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

There are many exciting advances happening in the field of mantle cell lymphoma.

Since its classification in 1994, the prognosis for patients diagnosed with mantle cell lymphoma (MCL) was generally poor; however, survival rates have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.

Moving from shock to action is hard, but it's critical to surviving cancer

Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.

Sometimes the people who inspire us are closer than we realize.

Do you know the difference between happiness and joy?

A higher complete response rate was seen in patients given both agents compared with those given Imbruvica alone.

The treatment landscape of mantle cell lymphoma is continuing to change. See what expert Andre Goy, M.D., has to say about it.

Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.

Kevin unleashes his inner guilt for the benefit of you, gentle readers.

You walk in and the entire staff yells your name, al la “Norm” of Cheers fame

Grzegorz S. Nowakowski, M.D., discusses the potential for genetic testing for patients with mantle cell lymphoma.

A non-runner explains why running and cancer are the same thing. Except they're not.

Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).

In this episode of Cancer With Kevin, we explore the unexpected humor that comes with the general awfulness

Cancer quickly becomes your new, unwelcome, family business

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

After two transplants and two relapses, it's time to go down a novel road.

If you've relapsed after you thought you'd been cured, you know what a shock it is. Relapsing twice, after two transplants, turns out to have a surprisingly different effect on Kevin.

Kevin compares building and fighting robots with enduring and fighting cancer-- a surprising synergy!